Sanofi Reiterates Alert on Proper Use of Jevtana; Five Deaths Reported Since Launch in September

Five of the approximately 200 patients administered Sanofi K.K.’s prostate cancer treatment Jevtana (cabazitaxel acetonate), which the company launched in September, had died as of early December, an early post-marketing phase vigilance (EPPV) report issued by the company and other...read more